Politics of Cancer

//Politics of Cancer

Political happenings that are related to Cancer

For USA readers – Protect Our Department of Defense Prostate Cancer Funding

UPDATE June &, 2016 4:30 PM EST We won. The Durbin Amendment to save all cancer research funding at the Department of Defense passed 66-32, saving the Congressionally Directed Medical Research Program (CDMRP), which includes an important prostate cancer funding resource. Thank you to everyone from Malecare Cancer Support and all of our partner organizations for sending in your emails and making your phone calls. Three cheers for you! To see how your Senators voted on this important matter go to the bottom of this post.  If your Senator voted YEA send an email thanking them.  However, if they voted [...]

By | June 2nd, 2016|DOD, DOD PCRP, Politics of Cancer, United States|0 Comments

Myriad Genetics Attempts To Deny Patients Their Personal Genetic Information

 In 2013, Myriad Genetic failed – in a case that was heard in the United States Supreme Court - to patent the BRCA1 and BRCA2 genes.  We all have these two genes which, when they mutate, are associated with breast, ovarian and prostate cancers. If Myriad succeeded, they would have controlled patents on these genes and could establish a monopoly on all research and testing of these genes. Myriad is now facing a lawsuit over  denying their clients access to their own genetic information.  The four plaintiffs in the action underwent genetic testing with Myriad to determine their hereditary risk [...]

Good News, The House Appropriations Committee Increases the Ask For The DoD PCRP Allocation for FY 2017

Today, I have some good news to share with you. Malecare, along with many other prostate cancer advocacy groups have been hard at work attempting to persuade members of Congress to not only maintain the Department of Defense Prostate Cancer Research Program (DoD PCRP), but to increase its funding for the next fiscal year. I am happy to report that we have successfully made the first, vital step towards accomplishing our goal! We have just found out that the congressional appropriators have recommend that Congress increases by $10 million fiscal year 2017 funding level. The U.S. House of Representatives' Committee [...]

Prostate Cancer drugs cost more in the USA than in other countries.

The cost of Enzalutamide (Xtandi) in the United States is being challenged by Knowledge Ecology International (KEI), a public interest advocacy group.  The average US wholesale price of Xtandi in 2015 was $88 per capsule.   That can add up to $129,000 annual cost per man. There are significant issues related to high costs of treatment. The higher the cost, the more likely that insurance companies will  require pre-authorization to cover the cost of the drug.  That means a man dealing with advanced stage disease is tasked with asking his doctor to spend uncompensated time fighting the insurance company for his [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー